Ruth M. Farrell, MD, MA, Marsha Michie, PhD, Christopher T. Scott, PhD, Rebecca Flyckt, MD, and Mary LaPlante, MD
One reason for neglect of women’s health as patients and subjects has been restrictions on uterine transfer of modified human embryos, a boundary that has now been crossed.
AMA J Ethics. 2019;21(12):E1071-1078. doi:
10.1001/amajethics.2019.1071.
Anne Drapkin Lyerly, MD, MA and Ruth R. Faden, PhD, MPH
Participation in a research study—in which there are rigorous standards and close monitoring—may be a safer context for the use of medications in pregnancy than the clinical setting, where the evidence base is lacking.
Christina Krudy, MD and Kavita Shah Arora, MD, MBE
Antenatal corticosteroids aren’t as effective in reducing neonatal mortality in low-income as high-income regions due to cultural and health care differences.
AMA J Ethics. 2018;20(3):261-268. doi:
10.1001/journalofethics.2018.20.3.stas1-1803.
J. Brian Szender, MD, MS and Shashikant B. Lele, MD
The estimated reduction in risk of ovarian cancer for any woman undergoing opportunistic removal of the Fallopian tubes is up to 50 percent, but whether removal is more beneficial than ligation has not been established.
AMA J Ethics. 2015;17(9):843-848. doi:
10.1001/journalofethics.2015.17.9.stas1-1509.
Amanda Fakih, MHSA and Kayte Spector-Bagdady, JD, MBE
Testing everyone for everything identifies more fetal conditions, but confusion persists about whether clinicians should leave screening decisions to patients.
AMA J Ethics. 2019;21(10):E858-864. doi:
10.1001/amajethics.2019.858.